This sponsored supplement was produced by Focus Reports.
Project Director: Béatrice Collet, Koen Liekens
Project Coordinator: Fleur Richard
Project Supervisor: Crystelle Coury
Copywriting: Andrey Muntyan, Manuel Mendoza
For exclusive interviews and more info, please log onto http://pharma.FocusReports.net or write to contact@focusreports.net
Hamangia: The Thinker and the Sitting Woman, Copyright Nicu Oprea
|
Increasing integration with the world economy and accession to the European Union (EU) in 2007 have been key pillars in taking
the growth potential of Romania's pharmaceutical market to greater heights. Valued at $3.3 billion, Romania was recently labeled
an IMS Tier 3 category of "Fast Followers" among the world's 17 pharmerging nations. "One of the larger EU members, Romania
stands for an incredible market opportunity in terms of size and population—9th and 27th in the EU, respectively—offering
investors a strong market potential as the second-largest country in Central and Eastern Europe (CEE) after Poland," explains
Sorin Vasilescu, director of the Foreign Investment Department under Romania's Ministry of Economy, Commerce and Business
Environment.
Regrettably, a European Commission (EC) and Organization for Economic Cooperation and Development (OECD) joint study from
2010 showed that Romania still has the lowest life expectancy in the entire EU. Historical analyses show how chronic underfunding
of the healthcare system has taken its toll on the Romanian patients. According to a June presentation of the Romanian Association
of International Medicines Manufacturers (ARPIM), current healthcare expenditures amount to only 3.6% of the country's GDP.
In comparison, the 2009 averages in the EU and Africa stood at 8.6% and 5.9%, respectively, putting Romania in the same line
with Madagascar and Burundi.
PharmExec Blog
Follow Us
RSS
Bookstore
